Pipeline
Treg Targeted Biologics for Immune-Mediated Diseases
Our pipeline of large molecules reflects TRexBio’s commitment to creating fit-for-purpose therapeutics with a focus on the tissue – where disease presents – offering new potential for safer, more effective, and more durable control of immune-mediated diseases. We have both wholly owned and partnered assets.
Atopic Dermatitis
TRB-061
- Preclinical
- IND Enabling
- Phase 1
- Phase 2
- Phase 3
TRB-061 is a novel TNFR2-selective agonist designed to activate and expand effector Tregs in the tissue and restore immune balance in inflammatory diseases. TRB-061 is in clinical development for moderate-to-severe atopic dermatitis (AD).
IMMUNOLOGY
TRB-071
- Preclinical
- IND Enabling
- Phase 1
- Phase 2
- Phase 3
TRB-061 is designed to reduce inflammation and promote barrier tissue repair by selectively expanding a highly activated subpopulation of Tregs that are preferentiatlly located in the tissue. TRB-061 is in clinical development for moderate-to-severe atopic dermatitis (AD), also known as eczema.
IMMUNOLOGY
TRB-081
- Preclinical
- IND Enabling
- Phase 1
- Phase 2
- Phase 3
TRB-061 is designed to reduce inflammation and promote barrier tissue repair by selectively expanding a highly activated subpopulation of Tregs that are preferentiatlly located in the tissue. TRB-061 is in clinical development for moderate-to-severe atopic dermatitis (AD), also known as eczema.
IMMUNOLOGY
TRB-051
Partner: Lilly
- Preclinical
- IND Enabling
- Phase 1
- Phase 2
- Phase 3
TRB-061 is designed to reduce inflammation and promote barrier tissue repair by selectively expanding a highly activated subpopulation of Tregs that are preferentiatlly located in the tissue. TRB-061 is in clinical development for moderate-to-severe atopic dermatitis (AD), also known as eczema.
Our Collaborations
Separate from our pipeline of wholly owned programs, we have collaborated with leading biopharma and academic partners to accelerate the discovery and development of novel immunology programs. Our partnership with Eli Lilly includes two programs, TRB-041 and TRB-051, identified and advanced using TRexBio’s Deep Biology Platform. We also partnered with Johnson & Johnson Innovative Medicine to explore new targets in immunology and inflammation.
